Inventiva S.A

Inventiva S.A. has appointed Chris Benecchi as its new Chief Operating Officer, effective immediately. Benecchi, who previously served as CEO of Motric Bio, an Aditum Bio company, will lead the company's operational activities as it approaches the readout of its NATiV3 Phase 3 study of lanifibranor in MASH, expected in the last quarter of 2026, and prepares for potential commercialization. Inventiva's CEO, Andrew Obenshain, highlighted Benecchi's commercial, operational, and launch experience, noting his proven track record in bringing medicines to patients. With 30 years of biopharmaceutical leadership, Benecchi has held various commercial and operational roles, and holds an MBA from Duke University's Fuqua School of Business and a Bachelor of Arts from Colby College.

Inventiva S.A. has a strongly bullish consensus sentiment with Buy ratings from all 9 analysts covering the stock, and a 1-year median price target of $15.75 implying an upside potential of over 325%. On June 12, the company fully repaid roughly €62 million of its existing EIB loans, including principal and accrued interest, and executed a buyback and cancellation of warrants linked to around 22.7 million EIB shares for a total repurchase price of €50 million, covering all Tranche A warrants and 700,000 Tranche B warrants. Inventiva also drew down €75 million in debt financing from lenders Claret Capital Partners and BlackRock, consisting of €35 million in Tranche A Senior Secured Convertible Debt and €40 million in Tranche B Senior Secured Amortized Debt, with a conversion price of €5.2893 on the Tranche A Convertible Bonds representing a 40% premium on the EURO-denominated offer price for the stock ADS. The company is a clinical-stage biopharmaceutical firm developing oral small-molecule therapies including Odiparcil and Lanifibranor, as well as a TGF-ß treatment for idiopathic pulmonary fibrosis.